Abstract
The treatment of patients with IBD has evolved towards biologic therapy, which seeks to target specific immune and biochemical abnormalities at the molecular and cellular level. Multiple genes have been associated with susceptibility to IBD, and many of these can be linked to alterations in immune pathways. These immune pathways provide avenues for understanding the pathogenesis of IBD and suggest future drug targets, such as the IL-12–IL-23 pathway. In addition, failed therapeutic drug trials can provide valuable information about pitfalls in study design, drug delivery and disease activity assessment. Future biologic drug development will benefit from the early identification of subsets of patients who are most likely to respond to therapy by use of biological markers of genetic susceptibility or immunologic susceptibility.
Key Points
-
Multiple genetic associations with IBD have been discovered in the past few years
-
Several susceptibility genes are associated with innate or adaptive immune system pathways and these pathways provide multiple targets for therapeutic intervention
-
Potential pitfalls in future biologic drug development relate to historically high placebo response rates in patients with IBD
-
Biological markers of disease activity, genetic susceptibility and immunologic susceptibility may significantly increase drug response rates relative to placebo
-
Future drug development should focus on subpopulations of patients with specific genetic and immunologic profiles who stand to benefit the most from targeted therapy
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Kappelman, M. D. et al. The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States. Clin. Gastroenterol. Hepatol. 5, 1424–1429 (2007).
Kappelman, M. D. et al. Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults. Gastroenterology 135, 1907–1913 (2008).
Drossman, D. A., Patrick, D. L., Mitchell, C. M., Zagami, E. A. & Appelbaum, M. I. Health-related quality of life in inflammatory bowel disease. Functional status and patient worries and concerns. Dig. Dis. Sci. 34, 1379–1386 (1989).
US Department of Health & Human Services US Food & Drug Administration [online], (2009).
Feagan, B. G. et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology 135, 1493–1499 (2008).
Sandborn, W. J. et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology 137, 1250–1260 (2009).
Feagan, B. G. et al. The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients. Am. J. Gastroenterol. 102, 794–802 (2007).
Loftus, E. V. et al. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial. Am. J. Gastroenterol. 103, 3132–3141 (2008).
Van Assche, G. et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N. Engl. J. Med. 353, 362–368 (2005).
Su, C., Lichtenstein, G. R., Krok, K., Brensinger, C. M. & Lewis, J. D. A meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn's disease. Gastroenterology 126, 1257–1269 (2004).
Su, C., Lewis, J. D., Goldberg, B., Brensinger, C. & Lichtenstein, G. R. A meta-analysis of the placebo rates of remission and response in clinical trials of active ulcerative colitis. Gastroenterology 132, 516–526 (2007).
Sandborn, W. J. et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 121, 1088–1094 (2001).
Rutgeerts, P. et al. Onercept for moderate-to-severe Crohn's disease: a randomized, double-blind, placebo-controlled trial. Clin. Gastroenterol. Hepatol. 4, 888–893 (2006).
Sandborn, W. J. et al. CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial. Gut 53, 1485–1493 (2004).
Reinisch, W. et al. Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study. Inflamm. Bowel Dis. doi:10.1002/ibd.21038.
Hommes, D. M. T. et al. Fontolizumab (HuZAF), a humanized anti-IFN-gamma antibody, has clinical activity and excellent toelrability in moderate to severe Crohn's disease [abstract]. Digestive Disease Week 2004 (2004).
Lewis, J. D. C-reactive protein: anti-placebo or predictor of response. Gastroenterology 129, 1114–1116 (2005).
Sandborn, W. J. et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology 122, 512–530 (2002).
Jones, R. et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clin. Gastroenterol. 6, 1218–1224 (2008).
Schreiber, S. et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 129, 807–818 (2005).
Ghosh, S. et al. Natalizumab for active Crohn's disease. N. Engl. J. Med. 348, 24–32 (2003).
Colombel, J. F. et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 132, 52–65 (2007).
Sandborn, W. J. et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 56, 1232–1239 (2007).
Humira™ (adalimumab) package insert (Abbott, 2002).
Van den Brande, J. M. et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 124, 1774–1785 (2003).
Yacyshyn, B. R. et al. Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease. Gut 51, 30–36 (2002).
Yacyshyn, B. et al. A randomized, double-masked, placebo-controlled study of alicaforsen, an antisense inhibitor of intercellular adhesion molecule 1, for the treatment of subjects with active Crohn's disease. Clin. Gastroenterol. Hepatol. 5, 215–220 (2007).
Miner, P. B. Jr, Wedel, M. K., Xia, S. & Baker, B. F. Safety and efficacy of two dose formulations of alicaforsen enema compared with mesalazine enema for treatment of mild to moderate left-sided ulcerative colitis: a randomized, double-blind, active-controlled trial. Aliment. Pharmacol. Ther. 23, 1403–1413 (2006).
van Deventer, S. J. et al. A phase II dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis. Aliment. Pharmacol. Ther. 23, 1415–1425 (2006).
Siegel, C. A., Marden, S. M., Persing, S. M., Larson, R. J. & Sands, B. E. Risk of lymphoma associated with combination anti-TNF and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin. Gastroenterol. Hepatol. 7, 874–881 (2009).
Remicade® (infliximab) package insert (Centocor, 2003).
Cimzia® (certolizumab pegol) package insert (UBC, 2008).
Pagnoux, C. et al. JC virus leukoencephalopathy complicating Wegener's granulomatosis. Joint Bone Spine 70, 376–379 (2003).
Feagan, B. G. et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N. Engl. J. Med. 352, 2499–2507 (2005).
Feagan, B. G. et al. Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. Clin. Gastroenterol. Hepatol. 6, 1370–1377 (2008).
US National Institutes of Health ClinicalTrials.gov [online], (2009).
Saruta, M. et al. Phenotype and effector function of CC chemokine receptor 9-expressing lymphocytes in small intestinal Crohn's disease. J. Immunol. 178, 3293–3300 (2007).
Panés, J. et al. Efficacy of an inhibitor of adhesion molecule expression (GI270384X) in the treatment of experimental colitis. Am. J. Physiol. Gastrointest. Liver Physiol. 293, G739–G748 (2007).
Johnson, F. R. et al. Crohn's disease patients' risk-benefit preferences: serious adverse event risks versus treatment efficacy. Gastroenterology 133, 769–779 (2007).
Shih, D. Q. & Targan, S. R. Immunopathogenesis of inflammatory bowel disease. World J. Gastroenterol. 14, 390–400 (2008).
Shih, D. Q., Targan, S. R. & McGovern, D. Recent advances in IBD pathogenesis: genetics and immunobiology. Curr. Gastroenterol. Rep. 10, 568–575 (2008).
Peyrin-Biroulet, L., Desreumaux, P., Sandborn, W. J. & Colombel, J. F. Crohn's disease: beyond antagonists of tumour necrosis factor. Lancet 372, 67–81 (2008).
Rutgeerts, P., Vermeire, S. & Van Assche, G. Biological therapies for inflammatory bowel diseases. Gastroenterology 136, 1182–1197 (2009).
Plevy, S. et al. A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis. Gastroenterology 133, 1414–1422 (2007).
Van Assche, G. et al. Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial. Gut 55, 1568–1574 (2006).
O'Neill, L. A. Targeting signal transduction as a strategy to treat inflammatory diseases. Nat. Rev. Drug Discov. 5, 549–563 (2006).
West, K. CP-690550, a JAK3 inhibitor as an immunosuppressant for the treatment of rheumatoid arthritis, transplant rejection, psoriasis and other immune-mediated disorders. Curr. Opin. Investig. Drugs 10, 491–504 (2009).
Barrett, J. C. et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat. Genet. 40, 955–962 (2008).
Franke, A. et al. Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility. Nat. Genet. 40, 1319–1323 (2008).
Silverberg, M. S. et al. Ulcerative colitis-risk loci on chromosomes 1p36 and 12q15 found by genome-wide association study. Nat. Genet. 41, 216–220 (2009).
Duerr, R. H. et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 314, 1461–1463 (2006).
Wang, K. et al. Diverse genome-wide association studies associate the IL12/IL23 pathway with Crohn disease. Am. J. Hum. Genet. 84, 399–405 (2009).
Papp, K. A. et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 371, 1675–1684 (2008).
Sandborn, W. J. et al. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology 135, 1130–1141 (2008).
Toedter, G. P. et al. Relationship of C-reactive protein with clinical response after therapy with ustekinumab in Crohn's disease. Am. J. Gastroenterol. 104, 2768–2773 (2009).
Kimball, A. B. et al. Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial. Arch. Dermatol. 144, 200–207 (2008).
Mannon, P. J. et al. Anti-interleukin-12 antibody for active Crohn's disease. N. Engl. J. Med. 351, 2069–2079 (2004).
Nestle, F. O., Kaplan, D. H. & Barker, J. Psoriasis. N. Engl. J. Med. 361, 496–509 (2009).
Sands, B. E. et al. Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn's disease. Inflamm. Bowel Dis. doi:10.1002/ibd.21159.
Nikolaus, S. et al. Increased secretion of pro-inflammatory cytokines by circulating polymorphonuclear neutrophils and regulation by interleukin 10 during intestinal inflammation. Gut 42, 470–476 (1998).
Berg, D. J. et al. Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses. J. Clin. Invest. 98, 1010–1020 (1996).
Schreiber, S. et al. Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group. Gastroenterology 119, 1461–1472 (2000).
Louis, E., Libioulle, C., Reenaers, C., Belaiche, J. & Georges, M. Genetics of ulcerative colitis: the come-back of interleukin 10. Gut 58, 1173–1176 (2009).
Steidler, L. et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 289, 1352–1355 (2000).
Oyama, Y. et al. Autologous hematopoietic stem cell transplantation in patients with refractory Crohn's disease. Gastroenterology 128, 552–563 (2005).
Taupin, P. OTI-010 Osiris Therapeutics/JCR Pharmaceuticals. Curr. Opin. Investig. Drugs 7, 473–481 (2006).
Osiris Therapeutics Osiris Discontinues Enrollment in Crohn's Study Due to Concerns with Trial Design [online].
Gonzalez, M. A., Gonzalez-Rey, E., Rico, L., Buscher, D. & Delgado, M. Adipose-derived mesenchymal stem cells alleviate experimental colitis by inhibiting inflammatory and autoimmune responses. Gastroenterology 136, 978–989 (2009).
Gonzalez-Rey, E. et al. Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsis. Gut 58, 929–939 (2009).
Garcia-Olmo, D. et al. Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Dis. Colon Rectum 52, 79–86 (2009).
Burman, J. H., Williams, J. A., Thompson, H. & Cooke, W. T. The effect of diversion of intestinal contents on the progress of Crohn's disease of the large bowel. Gut 10, 1054 (1969).
Melmed, G. Y. & Abreu, M. T. New insights into the pathogenesis of inflammatory bowel disease. Curr. Gastroenterol. Rep. 6, 474–481 (2004).
Rosenstiel, P., Till, A. & Schreiber, S. NOD-like receptors and human diseases. Microbes Infect. 9, 648–657 (2007).
Franchimont, D. et al. Deficient host-bacteria interactions in inflammatory bowel disease? The toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn's disease and ulcerative colitis. Gut 53, 987–992 (2004).
Gewirtz, A. T. et al. Dominant-negative TLR5 polymorphism reduces adaptive immune response to flagellin and negatively associates with Crohn's disease. Am. J. Physiol. Gastrointest. Liver Physiol. 290, G1157–G1163 (2006).
Torok, H. P., Glas, J., Tonenchi, L., Mussack, T. & Folwaczny, C. Polymorphisms of the lipopolysaccharide-signaling complex in inflammatory bowel disease: association of a mutation in the Toll-like receptor 4 gene with ulcerative colitis. Clin. Immunol. 112, 85–91 (2004).
Torok, H. P. et al. Crohn's disease is associated with a toll-like receptor-9 polymorphism. Gastroenterology 127, 365–366 (2004).
Abreu, M. T. et al. TLR4 and MD-2 expression is regulated by immune-mediated signals in human intestinal epithelial cells. J. Biol. Chem. 277, 20431–20437 (2002).
Cario, E. & Podolsky, D. K. Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect. Immun. 68, 7010–7017 (2000).
Hayashi, F. et al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 410, 1099–1103 (2001).
Bambou, J. C. et al. In vitro and ex vivo activation of the TLR5 signaling pathway in intestinal epithelial cells by a commensal Escherichia coli strain. J. Biol. Chem. 279, 42984–42992 (2004).
Lodes, M. J. et al. Bacterial flagellin is a dominant antigen in Crohn disease. J. Clin. Invest. 113, 1296–1306 (2004).
Hugot, J. P. et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 411, 599–603 (2001).
Watanabe, T., Kitani, A., Murray, P. J. & Strober, W. NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses. Nat. Immunol. 5, 800–808 (2004).
Papadakis, K. A. et al. Dominant role for TL1A/DR3 pathway in IL-12 plus IL-18-induced IFN-{gamma} production by peripheral blood and mucosal CCR9+ T lymphocytes. J. Immunol. 174, 4985–4990 (2005).
Takedatsu, H. et al. TL1A (TNFSF15) regulates the development of chronic colitis by modulating both T-helper 1 and T-helper 17 activation. Gastroenterology 135, 552–567 (2008).
Michelsen, K. S. et al. IBD-associated TL1A gene (TNFSF15) haplotypes determine increased expression of TL1A protein. PLoS One 4, e4719 (2009).
Arijs, I. et al. Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. Gut 58, 1612–1619 (2009).
Ferrante, M. et al. Predictors of early response to infliximab in patients with ulcerative colitis. Inflamm. Bowel Dis. 13, 123–128 (2007).
Esters, N. et al. Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn's disease. Am. J. Gastroenterol. 97, 1458–1462 (2002).
Vasiliauskas, E. A. et al. Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics. Gut 47, 487–496 (2000).
Gazdar, A. F. Personalized medicine and inhibition of EGFR signaling in lung cancer. N. Engl. J. Med. 361, 1018–1020 (2009).
Rosell, R. et al. Screening for epidermal growth factor receptor mutations in lung cancer. N. Engl. J. Med. 361, 958–967 (2009).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
G. Y. Melmed is on the speaker's bureau for Abbot, Proctor & Gamble, and Shire. He is also a Consultant for Amgen and UCB. S. R. Targan is a Consultant for Amgen, Elan, Proctor & Gamble, Prometheus, and Wyeth. He is also on the Board of Directors for Prometheus.
Supplementary information
Supplementary Table 1
The IBD biologic pipeline. (DOC 121 kb)
Rights and permissions
About this article
Cite this article
Melmed, G., Targan, S. Future biologic targets for IBD: potentials and pitfalls. Nat Rev Gastroenterol Hepatol 7, 110–117 (2010). https://doi.org/10.1038/nrgastro.2009.218
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2009.218
This article is cited by
-
Small heat shock protein CRYAB inhibits intestinal mucosal inflammatory responses and protects barrier integrity through suppressing IKKβ activity
Mucosal Immunology (2019)
-
Interleukin 27 is up-regulated in patients with active inflammatory bowel disease
Immunologic Research (2016)
-
The Genetic Architecture of Alopecia Areata
Journal of Investigative Dermatology Symposium Proceedings (2013)
-
TL1A/TNFSF15 directly induces proinflammatory cytokines, including TNFα, from CD3+CD161+ T cells to exacerbate gut inflammation
Mucosal Immunology (2013)
-
Opposing consequences of IL-23 signaling mediated by innate and adaptive cells in chemically induced colitis in mice
Mucosal Immunology (2012)